News
![5 Reasons to Buy AT&T Stock Right Now: https://g.foolcdn.com/editorial/images/743134/gettyimages-1090008690.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelZyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1fb57907691cd70f7d670548d7d027551edeeed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1090008690.jpg?locale=us)
5 Reasons to Buy AT&T Stock Right Now
A quick look at AT&T's (NYSE: T) stock chart is enough to scare away most investors. You'd have to go back to the early 1990s to find the stock trading at a similar level as today.
There are
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Is AbbVie Still a Good Dividend Stock to Buy?: https://g.foolcdn.com/editorial/images/741720/a-person-delivering-a-presentation-getty.jpg](https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTVxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4ecc6a7db2d6b1cdbb3008814590881b4eeb4286/a-person-delivering-a-presentation-getty.jpg?locale=us)
Is AbbVie Still a Good Dividend Stock to Buy?
How do you know when a former favorite dividend stock is no longer one you should buy, or hold? Some would say it's time to look away as soon as the profits the company uses to make dividend
![2 High-Yield Dividend Stocks to Buy on the Dip: https://g.foolcdn.com/editorial/images/742379/physician-shaking-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0ZxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfe959a9055e3f70521f9ee9bccade7c4cccff27/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-shaking-patients-hand.jpg?locale=us)
2 High-Yield Dividend Stocks to Buy on the Dip
Income-seeking investors tend to be drawn to high dividend yields. The higher the yield, the better a dividend becomes at generating income that can fund an investor's spending as well as beat
![Is This Blue Chip Dividend Stock a Buy for Growth Investors?: https://g.foolcdn.com/editorial/images/742845/a-doctor-examines-a-patient-with-a-stethoscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1ZxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--424e13bc98eb638170a0f1af47103a76729932de/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-examines-a-patient-with-a-stethoscope.jpg?locale=us)
Is This Blue Chip Dividend Stock a Buy for Growth Investors?
The right companies can help investors improve their personal balance sheets. That is because businesses that reliably grow sales and earnings become more valuable to financial markets with each
![MannKind (MNKD) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
MannKind (MNKD) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
MannKind (NASDAQ: MNKD)Q2 2023 Earnings CallAug 07, 2023, 5:00 p.m. ET
Operator
Source Fool.com
![Why BioNTech Stock Was Sinking Today: https://g.foolcdn.com/editorial/images/743103/person-about-to-receive-a-vaccine-shot.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFJxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ab6d310807bd69e65c9dcb9daf2659194c5a2fce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-about-to-receive-a-vaccine-shot.jpg?locale=us)
Why BioNTech Stock Was Sinking Today
A monster revenue miss was the big reason for the widespread investor sell-off in BioNTech (NASDAQ: BNTX) stock on Monday. As of late-session trading that day, the once-hot biotech's share price had
![Why Shares of Mesoblast Are Down Monday: https://g.foolcdn.com/editorial/images/743045/physician-going-over-results-with-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTlxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--06250b222cdeff16d6da691f607f96a255faa1d6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-going-over-results-with-patient.jpg?locale=us)
Why Shares of Mesoblast Are Down Monday
Shares of Mesoblast (NASDAQ: MESO) were down by more than 15% as of 11:45 a.m. ET on Monday, just days after the healthcare stock plunged more than 61% on bad news regarding one of its lead therapy
![Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Axsome Therapeutics (NASDAQ: AXSM)Q2 2023 Earnings CallAug 07, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Why Sage Therapeutics Stock Is Crashing Today: https://g.foolcdn.com/editorial/images/743041/fda-not-approved.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUZxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1d7697ffc41349fbe79cfaf9e80cdcde1c555ee1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/fda-not-approved.jpg?locale=us)
Why Sage Therapeutics Stock Is Crashing Today
Shares of Sage Therapeutics (NASDAQ: SAGE) were crashing 51.2% lower as of 11:27 a.m. ET on Monday. The huge sell-off came after the company and its partner, Biogen, announced following the market
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![2 Top Biotech Stocks to Buy in August: https://g.foolcdn.com/editorial/images/742017/doctor-and-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMkZwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3aac7acde9942be61360186667242420453ab4bf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-talking.jpg?locale=us)
2 Top Biotech Stocks to Buy in August
Last year was no small challenge for many investors, but the tides appear to have shifted for the better so far in 2023. Some companies have even performed well throughout all these ups and downs.
![2 Top Stocks to Buy in August and Hold Forever: https://g.foolcdn.com/editorial/images/742251/physician-giving-medicine-to-elderly-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlZwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--714da7845e29d2e584bd882934874fc5819f73d7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-medicine-to-elderly-patient.jpg?locale=us)
2 Top Stocks to Buy in August and Hold Forever
Technological progress sometimes renders products or entire industries completely obsolete. That's true even within the healthcare sector, which as a whole is unlikely to fall out of style anytime
![1 Top Dividend Growth Stock to Buy on the Dip: https://g.foolcdn.com/editorial/images/742026/patient-talking-with-a-physician.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2RwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--17c1cfe8a44bcbedd529fe108a8eddd2966fd1b7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-talking-with-a-physician.jpg?locale=us)
1 Top Dividend Growth Stock to Buy on the Dip
Biotech giant Amgen (NASDAQ: AMGN) isn't having a great year. Its shares are down by 12% since 2023 started, and the company has faced several issues recently that have harmed its financial results
![3 Fantastic Growth Stocks to Buy in August: https://g.foolcdn.com/editorial/images/742707/smiling-man-holding-fist-up.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzFvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3b6879fcb39ea47e2dfe744c099dd3764eaa857b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/smiling-man-holding-fist-up.jpg?locale=us)
3 Fantastic Growth Stocks to Buy in August
What's a great thing to do during the hot month of August? One option is to find somewhere cool. Another is to invest in stocks that could deliver their own kind of sizzle.
We asked three Motley
![Why Shares of Mesoblast Are Plunging Friday: https://g.foolcdn.com/editorial/images/742876/guardant.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjlvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--19d0e03cd048b5e20bfc262f389fb6e5f77937e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/guardant.jpg?locale=us)
Why Shares of Mesoblast Are Plunging Friday
Shares of Mesoblast (NASDAQ: MESO) were down more than 61% as of 2:15 p.m. on Friday. The pharmaceutical stock is down more than 54% so far this year.
Mesoblast focuses on allogeneic cellular
![If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today: https://g.foolcdn.com/editorial/images/742219/a-doctor-takes-a-patients-blood-pressure.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM05vYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f9cc48c70a55f812ab01eb5b78ffbc32fbbcc8a6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-takes-a-patients-blood-pressure.jpg?locale=us)
If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today
Few other investment vehicles have arguably done more to enrich investors than the U.S. stock market. For example, A $5,000 investment in the S&P 500 index executed 10 years ago in 2013 would be
![Does Abbott Laboratories' Dividend Make It a Buy?: https://g.foolcdn.com/editorial/images/742227/investor-sits-on-couch-and-looks-at-laptop-in-consternation.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2hvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1cdac2dfc8a2a9413e6ba1cde6798eabeb80922d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-sits-on-couch-and-looks-at-laptop-in-consternation.jpg?locale=us)
Does Abbott Laboratories' Dividend Make It a Buy?
When you're in the market for dividend income, it's important to keep your eye on the long term. An attractive payout today isn't worth much if the company might be forced to reduce or cut its
![Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years: https://g.foolcdn.com/editorial/images/742230/investors-smile-as-one-signs-a-contract.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWxvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ce690940cbc18c7faf816ebacb06aaeab623037c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investors-smile-as-one-signs-a-contract.jpg?locale=us)
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
Especially if you're living on a fixed income, being able to bring in even $1,500 in extra money each year via dividends can be a big change for the better. But it's often difficult to figure out
![Is AbbVie Stock a Buy for Income Investors?: https://g.foolcdn.com/editorial/images/742413/a-customer-shops-at-a-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--12f80a078b828a06764411d536d38a23c5d9dfcf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-customer-shops-at-a-pharmacy.jpg?locale=us)
Is AbbVie Stock a Buy for Income Investors?
There are very few constants in life. But bills coming in on a routine basis is one of them. This is what makes income investing an appealing strategy for investors to generate the cash flow
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Dynavax Technologies (DVAX) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Dynavax Technologies (NASDAQ: DVAX)Q2 2023 Earnings CallAug 03, 2023, 4:30 p.m. ET
Operator
Source Fool.com
![Geron (GERN) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Geron (GERN) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q2 2023 Earnings CallAug 03, 2023, 4:30 p.m. ET
Aron Feingold
Source Fool.com
![EQS-News: Newron announces H1 2023 results and provides R&D update: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelB3SXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--521237387ec8207326f44117d145b81c1391bc28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_color_high_res.jpg?locale=us)
EQS-News: Newron announces H1 2023 results and provides R&D update
![Why Coherus BioSciences Stock Popped Today: https://g.foolcdn.com/editorial/images/742616/lab-research-scientists-women-in-stem.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlpuYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--93e4eca21dcccbab2733f876a6e12c44c7d97a80/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/lab-research-scientists-women-in-stem.jpg?locale=us)
Why Coherus BioSciences Stock Popped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) soared 17.7% on Thursday, according to data provided by S&P Global Market Intelligence, after the biotech company announced better-than-expected